Public, NASDAQ:HALO
NASDAQ Global Market
ZNGA, AMLN, YOKU, RAX Among Charts to Watch
Date: Fri, 03 Feb 2012 05:23:38 GMT
Tags:
ZNGA, AMLN, YOKU, RAX Among Charts to Watch
AdviceTrade (blog) - Feb 3, 2012
AdviceTrade (blog) - Feb 3, 2012
by Harry Boxer, www.TheTechTrader.com Despite the fact that the market had its ups and downs on Thursday, there were a lot of stocks that we follow that did very well, so we'll go over some of those.
14 Rallying Biotech Stocks Being Snapped Up By Insiders
Date: Thu, 02 Feb 2012 06:17:14 GMT
Tags:
14 Rallying Biotech Stocks Being Snapped Up By Insiders
Seeking Alpha - Feb 2, 2012
Seeking Alpha - Feb 2, 2012
Want to know the inside scoop? One of the best sources for what company insiders actually think about their companies is trends in insider buying.
KTCC, MDVN, STX, BVSN Among Charts to Watch
Date: Thu, 02 Feb 2012 03:59:09 GMT
Tags:
KTCC, MDVN, STX, BVSN Among Charts to Watch
AdviceTrade - Feb 2, 2012
AdviceTrade - Feb 2, 2012
by Harry Boxer, www.TheTechTrader.com The market had another wonderful day on Wednesday. It was one of the better trading days this year at TheTechTrader.
HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial
Date: Wed, 01 Feb 2012 11:27:41 GMT
Tags:
HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial
Sacramento Bee - Feb 1, 2012
Sacramento Bee - Feb 1, 2012
By Halozyme Therapeutics, Inc. SAN DIEGO, Jan. 31, 2012 -- /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented interim results from the Phase 1 proof-of-concept and local tolerability study of HTI-501 (an investigational, ...
HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial
Date: Tue, 31 Jan 2012 21:06:41 GMT
Tags:
HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial
PR Newswire (press release) - Jan 31, 2012
PR Newswire (press release) - Jan 31, 2012
SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented interim results from the Phase 1 proof-of-concept and local tolerability study of HTI-501 (an investigational, conditionally active recombinant human ...
Halozyme's New High
Date: Wed, 01 Feb 2012 23:29:20 GMT
Tags:
HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial
Date: Tue, 31 Jan 2012 21:05:00 GMT
Tags:
[PR Newswire] - SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO - News) today presented interim results from the Phase 1 proof-of-concept and local tolerability study of HTI-501 (an investigational, ...
5 Stocks Setting Up to Break Out
Date: Tue, 31 Jan 2012 17:46:30 GMT
Tags:
The Giants, Ravens And 49ers Of Biotech
Date: Fri, 20 Jan 2012 20:41:55 GMT
Tags:
The Squeeze Is On
Date: Thu, 19 Jan 2012 16:08:30 GMT
Tags: